Parke-Davis for use in a multi-center cardiovascular drug research trial.

"Arterial elasticity is an important factor in cardiovascular disease research and we are excited about Parke-Davis’ use of the HDI/PulseWaveä CR-2000 to obtain information on both large and small artery elasticity in support of their research," said Dennis L. Sellke, CEO of HDI.

Stephen P. Glasser, M.D., Principal Investigator of the trial and Director of Graduate Studies in Clinical Research and Professor of Epidemiology at the University of Minnesota’s School of Public Health says: "It is my belief that arterial elasticity represents one of the earliest markers of vascular disease. Thus, matching HDI’s innovative technique with the Parke-Davis clinical trial will provide some interesting information about the cardiovascular disease process."

Jay N. Cohn, M.D., Professor of Medicine in the Cardiovascular Division at the University of Minnesota, author of more than 500 scientific publications and a member of HDI’s Board of Directors says, "the HDI/PulseWaveä CR-2000 Instrument is easy-to-use and is the most sensitive method available today, non-invasively or invasively, to obtain research information on the small arteries."

The HDI/PulseWaveä CR-2000 Instrument became available in late 1998 and is receiving worldwide acceptance as a premier research tool. The HDI/PulseWaveä CR-2000 Instrument allows researchers to non-invasively assess changes in a research subject’s endothelial function when studying pharmaceutical compounds, lifestyle changes and other cardiovascular risk factors.

Cardiovascular disease accounts for one-half of all deaths in the United States each year and is the primary cause of heart attacks and strokes. The disease can manifest itself in many ways: hypertension, coronary artery disease, peripheral artery disease, atherosclerosis, aneurysm, stroke, kidney failure, and retinopathy.

Hypertension Diagnostics has developed proprietary cardiovascular profiling technology that analyzes non-invasively derived arterial pulse pressure waveform data as a means of providing parameters that are useful in assessing the cardiovascular system. The Company has designed two models of the HDI/PulseWaveä CardioVascular Profiling Instrument: (1) the CR-2000 which is currently in use by physician scientists for research purposes only; and (2) the DO-2020 which is intended to assist physicians and other health care professionals in screening, diagnosing and monitoring the treatment of patients with cardiovascular disease. The Company has not yet received permission to market the DO-2020 from the Food and Drug Administration.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 1998 Annual Report on Form 10-KSB under the caption "Risk Factors," as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company's ability to receive regulatory approval for its Model DO-2020 product; the availability of third-party reimbursements; market acceptance of the Company's products; timely development of the Central Data Management Facility (CDMF); the ability of third parties to manufacture the Company's products on a commercial scale and in compliance with regulatory requirements; the availability of integral components for the Company's products; the Company's ability to develop distribution channels; increased competition; changes in government regulation; health care reform; exposure to potential product liability; and the Company's ability to protect its proprietary technology.

HDI/PulseWave is a trademark of Hypertension Diagnostics Inc.